Abstract:Yashi Ruan, 1, &ast Lixia Guan, 2, &ast Yuting Wang, 2 Yifei Geng, 2 Xiaoran Wang, 2 Miao-Miao Niu, 2 Li Yang, 1 Cen Xu, 1 Zhen Xu 1 1 Department of Urology, Reproductive Medicine and Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, People's Republic of China; 2 Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li Yang; Cen Xu, Department of Urology, Reproductive Medicine and Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, 225300, People's Republic of China, Email ; Purpose: Dual inhibition of ataxia telangiectasia mutated (ATM) and histone deacetylase 2 (HDAC2) may be a potential strategy to improve antitumor efficacy in testicular cancer. Methods: A combined virtual screening protocol including pharmacophore modeling and molecular docking was used for screening potent dual-target ATM/HDAC2 inhibitors. In order to obtain the optimal lead compound, the dual ATM/HDAC2 inhibitory activity of the screened compounds was further evaluated using enzyme inhibition methods. The binding stability of the optimal compound to the dual targets was verified by molecular dynamics (MD) simulation. MTT assay and in vivo antitumor experiment were performed to validate antitumor efficacy of the optimal compound in testicular cancer. Results: Here, we successfully discovered six potent dual-target ATM/HDAC2 inhibitors (AMHs 1– 6), which exhibited good inhibitory activity against both ATM and HDAC2. Among them, AMH-4 showed strong inhibitory activity against both ATM (IC 50 = 1.12 ± 0.03 nM) and HDAC2 (IC 50 = 3.04 ± 0.08 nM). MD simulation indicated that AMH-4 binds to ATM and HDAC2 with satisfactory stability. Importantly, AMH-4 had significant antiproliferative activity on human testicular tumor cells, especially NTERA-2 cL.D1 cells, and no inhibitory effect on normal human testicular cells. In vivo experiments exhibited that AMH-4 was more effective than lartesertib and vorinostat in inhibiting the growth of NTERA-2 cL.D1 xenograft tumors with low toxicity. Conclusion: Overall, these results suggest that AMH-4 is an effective and low toxicity candidate for the treatment of testicular germ cell tumors. Keywords: ataxia telangiectasia mutated, histone deacetylase 2, dual-targeting inhibitors, testicular germ cell tumors, structure-based virtual screening Testicular germ cell tumors (TGCT) are the most common type of testicular malignancy, emerging most frequently in males between the ages of 15 and 40. 1,2 During the past 20 years, the incidence of testicular cancer has continued to rise in many countries and is expected to increase further in the future. 3,4 Currently, surgery and standard-dose chemotherapy are the main methods of treating TGCT. 5 Approximately 80–90% of metastatic TGCT have a high cure rate after standard dose cisplatin chemotherapy. 5 However, testicular cancer survivors treated with cisplatin face many toxic side effects, including ototoxicity, neuropathy, cardiovascular toxicity, infertility, and secondary malignancies. 6 In addition, young patients may face a range of long-term psychosocial issues after treatment, including mental health, gender relations and work issues, which can significantly affect their overall quality of life. 7 For TGCT-resistant patients who have failed multiple chemotherapy regimens, the clinical cure rate is extremely low. 6 Therefore, the development of novel drugs for testicular cancer is indeed urgent. At present, dual-target therapy is a promising treatment strategy with fewer side effects, lower toxicity, and the potential to overcome drug resistance in cancer treatment. 8–10 ATM plays a central role in protecting the genome from DNA damage through intact DNA repair pathways. 11–13 There are growing evidences suggest that ATM can coordinate homologous recombination (HR) and non-homologous end joining (NHEJ) pathways to repair DNA double-strand breaks (DSBs) and maintain genomic integrity. 11,14,15 In response to DSBs, ATM kinase undergoes self-phosphorylation and subsequently phosphorylates several downstream substrates, including p53, p21, Nbs1, and KAP1, ultimately mediating DNA repair and cell cycle regulation. 12,16,17 Studies have shown that abnormal ATM, characterized by serine 1981 phosphorylation, can be observed in testicular germ cell tumors. 18 Therefore, the inhibiti -Abstract Truncated-

Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study

Discovery of [1,2,3]Triazolo[4,5-C]quinoline Derivatives As a New Class of Ataxia-Telangiectasia Mutated Kinase Inhibitors

Progress of ATM Inhibitors: Opportunities and Challenges

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Small Molecular Inhibitors That Target ATM for Drug Discovery: Current Research and Potential Prospective

Computational Analysis of Non-synonymous SNPs in ATM Kinase: Structural Insights, Functional Implications, and Inhibitor Discovery

ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I

Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening

Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo

Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)

Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies

Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors

Abstract 7127: An ATM inhibitor: ZN-B-2262 in combination with radiation/ADCs containing topoisomerase inhibitors for the treatment of solid tumors

Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer

Abstract 2604: the Novel ATR Inhibitor ATG-018 is Efficacious in Preclinical Cancer Models

Discovery of a Novel and Potent Dual-Targeting Inhibitor of ATM and HDAC2 Through Structure-Based Virtual Screening for the Treatment of Testicular Cancer

Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer

Identification of ATM Mutation As a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy

Antisense Inhibition of ATM Gene Enhances the Radiosensitivity of Head and Neck Squamous Cell Carcinoma in Mice

Discovery of novel 7,7-dimethyl-6,7-dihydro-5 H -pyrrolo[3,4- d ]pyrimidines as ATR inhibitors based on structure-based drug design